Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av Enpatoran hos deltagare med kutan manifestation av lupus med eller utan systemisk sjukdom (ELOWEN-1)

En fas 3, randomiserad, dubbelblind, placebokontrollerad parallellstudie för att utvärdera effektiviteten och säkerheten hos Enpatoran hos deltagare med aktiva kutan manifestationer av lupus erythematosus med eller utan systemisk sjukdom som får standardvård (Elowen-1)

The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include:

Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo.

Intervention Form: Film-coated tablet.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

202

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • New South Wales
      • New Lambton Heights, New South Wales, Australien, 2305
        • Rekrytering
        • John Hunter Hospital - PARENT
    • Queensland
      • Maroochydore, Queensland, Australien, 4558
        • Rekrytering
        • Rheumatology Research Unit Sunshine Coast
    • Victoria
      • Melbourne, Victoria, Australien, 3004
        • Rekrytering
        • The Alfred Hospital - PARENT
      • Leuven, Belgien, 03000
        • Rekrytering
        • UZ Leuven - Internal Medicine
    • Ceará
      • Fortaleza, Ceará, Brasilien, 60430-370
        • Rekrytering
        • HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasilien, 40150-150
        • Rekrytering
        • Clínica SER da Bahia
    • Mato Grosso
      • Cuiabá, Mato Grosso, Brasilien, 78020-500
        • Rekrytering
        • IPC MT Instituto de Pesquisas Clinicas do Mato Grosso
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brasilien, 30150-221
        • Rekrytering
        • Freire Pesquisa Clinica
    • São Paulo
      • Barretos, São Paulo, Brasilien, 14784400
        • Rekrytering
        • Hospital de Câncer de Barretos - Fundação Pio XII - Hospital de Amor de Barretos
      • Plovdiv, Bulgarien, 4023
        • Rekrytering
        • DCC V Plovdiv Sv. Archbishop Luka EOOD
      • Sofia, Bulgarien, 1407
        • Rekrytering
        • Ambulatory for Specialized Medical Help - skin and venereal diseases
      • Paris, Frankrike, 75020
        • Rekrytering
        • Hopital Tenon - service dermatologie et centre d'allergie
    • Pays de la Loire Region
      • Saint-Étienne-de-Montluc, Pays de la Loire Region, Frankrike, 42055
        • Rekrytering
        • CHU Saint Etienne - Hôpital Nord - service de medecine interne
    • California
      • Los Angeles, California, Förenta staterna, 90045
        • Rekrytering
        • Dermatology Research Associates - 300204025
      • Thousand Oaks, California, Förenta staterna, 91360
        • Rekrytering
        • Cohen Medical Centers
    • Florida
      • Cooper City, Florida, Förenta staterna, 33024
        • Rekrytering
        • GNP Research at Mark Jaffe, MD
      • Miami, Florida, Förenta staterna, 33135
        • Rekrytering
        • Advance Medical Research Center
      • Miami, Florida, Förenta staterna, 33175
        • Rekrytering
        • Diverse Clinical Research LLC
      • Tamarac, Florida, Förenta staterna, 33321
        • Rekrytering
        • D&H National Research Centers, Inc.
      • Tampa, Florida, Förenta staterna, 33606
        • Rekrytering
        • Clinical Research of West Florida, Inc.
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30303
        • Rekrytering
        • Emory University School of Medicine
    • Michigan
      • Troy, Michigan, Förenta staterna, 48084
        • Rekrytering
        • Revival Research Institute, LLC
    • Texas
      • Allen, Texas, Förenta staterna, 75013
        • Rekrytering
        • Allen Arthritis
      • Allen, Texas, Förenta staterna, 75013
        • Rekrytering
        • Arthritis and Rheumatology Research Institute PLLC
      • Corpus Christi, Texas, Förenta staterna, 78415
        • Rekrytering
        • Arthritis Care of Texas
      • Ramat Gan, Israel, 5265601
        • Rekrytering
        • Chaim Sheba Medical Center - pt
      • Roma, Italien, 00155
        • Rekrytering
        • Università Campus Bio-Medico di Roma - UOC Reumatologia
    • Firenze
      • Florence, Firenze, Italien, 50125
        • Rekrytering
        • Azienda USL Toscana Centro - Ospedale Piero Palagi
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 457-8510
        • Rekrytering
        • JCHO Chukyo Hospital - Dept of Dermatology
    • Chiba
      • Chiba, Chiba, Japan, 260-8712
        • Rekrytering
        • NHO Chibahigashi National Hospital - Dept of Allergy/Rheumatology
    • Fukuoka
      • Kitakyushu-shi, Fukuoka, Japan, 807-8556
        • Rekrytering
        • Hospital of the University of Occupational and Environmental Health - Dept of Dermatology
    • Fukushima
      • Fukushima, Fukushima, Japan, 960-1295
        • Rekrytering
        • Fukushima Medical University Hospital - Dept of Rheumatology/Immunology
    • Hokkaido
      • Asahikawa-shi, Hokkaido, Japan, 070-8644
        • Rekrytering
        • NHO Asahikawa Medical Center - Dept of Gastroenterology
      • Sapporo, Hokkaido, Japan, 060-8604
        • Rekrytering
        • Sapporo City General Hospital - Dept of Rheumatology/Immunology
    • Hyōgo
      • Kobe, Hyōgo, Japan, 650-0017
        • Rekrytering
        • Kobe University Hospital - Dept of Immunology/Rheumatology
    • Ishikawa-ken
      • Kanazawa, Ishikawa-ken, Japan, 920-8641
        • Rekrytering
        • Kanazawa University Hospital - Dept of Rheumatology/Immunology
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 236-0004
        • Rekrytering
        • Yokohama City University Hospital - Dept of Dermatology
    • Miyagi
      • Sendai, Miyagi, Japan, 983-8512
        • Rekrytering
        • Tohoku Medical and Pharmaceutical University Hospital - Dept of Hematology/Rheumatology
    • Okayama-ken
      • Okayama, Okayama-ken, Japan, 700-8558
        • Rekrytering
        • Okayama University Hospital - Dept of Rheumatology/Immunology
    • Osaka
      • Suita-shi, Osaka, Japan, 565-0871
        • Rekrytering
        • The University of Osaka Hospital - Dept of Dermatology
    • Tokyo
      • Bunkyo-ku, Tokyo, Japan, 113-8519
        • Rekrytering
        • Institute of Science Tokyo Hospital - Dept of Dermatology
      • tabashi City, Tokyo, Japan, 173-8610
        • Rekrytering
        • Nihon University Itabashi Hospital - Dept of Hematology/Immunology
    • Tokyo-To
      • Chūōku, Tokyo-To, Japan, 104-8560
        • Rekrytering
        • St. Luke's International Hospital - Dept of Immunology/Allergy
    • Yamanashi
      • Chūō, Yamanashi, Japan, 409-3898
        • Rekrytering
        • University of Yamanashi Hospital - Dept of Rheumatology/Immunology
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510080
        • Rekrytering
        • Guangdong Provincial People's Hospital
    • Jiangxi
      • Ganzhou, Jiangxi, Kina, 341000
        • Rekrytering
        • Ganzhou People's Hospital - 300165192
      • Krakow, Polen, 30-348
        • Rekrytering
        • Centrum Badan Klinicznych JCI
      • Lublin, Polen, 20-412
        • Rekrytering
        • ETG Lublin - ETG NETWORK Sp. z o.o.
      • Malbork, Polen, 82-200
        • Rekrytering
        • Centrum Badawcze Panaceum Agnieszka Brzezicka, Magdalena Lenkiewicz Sp. z o.o.
      • Rzeszów, Polen, 35-055
        • Rekrytering
        • Uniwersytecki Szpital Kliniczny im Fryderyka Chopina w Rzeszowie - Klinika Dermatologii i Dermatologii Onkologicznej
      • Rzeszów, Polen, 35-309
        • Rekrytering
        • SOMED CR
      • Warsaw, Polen, 04-305
        • Rekrytering
        • REUMA CENTRUM Specjalistyczna Praktyka Lekarska Dr n. med. Jakub Trefler
      • Zamość, Polen, 22-400
        • Rekrytering
        • Velocity Zamosc
      • Brasov, Rumänien, 500299
        • Rekrytering
        • Futuremeds S R L.
      • Basel, Schweiz, 4031
        • Rekrytering
        • Universitaetsspital Basel - Klinik fuer Dermatologie
      • Sankt Gallen, Schweiz, 9000
        • Rekrytering
        • Kantonsspital St. Gallen - Klinik f. Dermatologie, Venerologie u Allergologie
      • Bratislava, Slovakien, 81369
        • Rekrytering
        • Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto - Dermatovenerologicka klinika
      • Košice, Slovakien, 04011
        • Rekrytering
        • Artromac n.o. - Reumatologicka ambulancia
      • Valencia, Spanien, 46014
        • Rekrytering
        • Hospital General Universitario de Valencia - Rheumatology
    • La Coruña
      • Santiago de Compostela, La Coruña, Spanien, 15706
        • Rekrytering
        • Complejo Hospitalario Universitario de Santiago - Dermatology Unit
    • Navarre
      • Pamplona, Navarre, Spanien, 31008
        • Rekrytering
        • Complejo Hospitalario de Navarra - Nefrologia
    • Greater London
      • London, Greater London, Storbritannien, E11 1NR
        • Rekrytering
        • Whipps Cross University Hospital - Dept of Rheumatology
    • Tyne & Wear
      • Newcastle upon Tyne, Tyne & Wear, Storbritannien, NE7 7DN
        • Rekrytering
        • Freeman Hospital - Dept of Rheumatology
      • Incheon, Sydkorea, 21565
        • Rekrytering
        • Gachon University Gil Medical Center
      • Seoul, Sydkorea, 04763
        • Rekrytering
        • Hanyang University Seoul Hospital - 300186741
    • Gyeonggi-do
      • Ansan-si, Gyeonggi-do, Sydkorea, 15355
        • Rekrytering
        • Korea University Ansan Hospital - 300133335
      • Seongnam-si, Gyeonggi-do, Sydkorea, 13620
        • Rekrytering
        • Seoul National University Bundang Hospital
      • Taichung, Taiwan, 404332
        • Rekrytering
        • China Medical University Hospital
      • Tainan, Taiwan, 71004
        • Rekrytering
        • Chi Mei Medical Center - 300192662
      • Bangkok, Thailand, 10400
        • Rekrytering
        • Ramathibodi Hospital - 300195177
    • Changwat Pathum Thani
      • Amphur Klongluang, Changwat Pathum Thani, Thailand, 12120
        • Rekrytering
        • Thammasat University Hospital
      • Berlin, Tyskland, 10117
        • Rekrytering
        • Charité - Campus Charité Mitte - Klinik fuer Dermatol., Venerol., Allergologie
      • Dresden, Tyskland, 01307
        • Rekrytering
        • Universitaetsklinikum Carl Gustav Carus TU Dresden
    • Lower Saxony
      • Buxtehude, Lower Saxony, Tyskland, 21614
        • Rekrytering
        • Elbekliniken Buxtehude GmbH - Dermatologie

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria

  • Vaccinations are up to date according to local guidelines/recommendations. Recombinant zoster vaccination is encouraged but not mandatory.
  • Participants with diagnosis of Discoid Lupus Erythematosus (DLE) and/or Subacute Cutaneous Lupus Erythematosus (SCLE) documented in medical history, with or without Systemic Lupus Erythematosus (SLE).
  • Participants with active Acute Cutaneous Lupus Erythematosus (ACLE) as sole cutaneous manifestations is allowed in the presence of SLE and should be present for at least 6 weeks prior to the Screening visit.
  • Participants with diagnosis of SLE fulfilling the European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 classification criteria, must have active DLE and/or SCLE and/or ACLE.

For participants with SLE:

  • Participants with diagnosis of SLE and fulfill EULAR/ACR 2019 classification criteria.
  • Participants with disease duration (cutaneous disease and, where applicable, SLE) of >= 6 months from time of diagnosis to Screening.
  • Participants with CLASI-A score >= 8 at Screening and Day 1 visits.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • Participants with primary diagnosis of autoimmune rheumatic disease (e.g., systemic sclerosis, rheumatoid arthritis) other than Cutaneous Lupus Erythematosus (CLE) and SLE.
  • Participants with any condition including dermatological diseases other than cutaneous manifestations of lupus (e.g. psoriasis), any uncontrolled disease (e.g. asthma, chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasis, pulmonary arterial hypertension), or life-threatening manifestations of lupus (e.g. active systemic vasculitis) that in Investigator's or Sponsor/designee's opinion constitutes inappropriate risk or contraindication for participation.
  • Participants with drug-induced lupus (SLE or CLE).
  • Participants with active lupus nephritis on induction therapy, or induction therapy completed within 3 months of the Screening visit (stable maintenance therapy with either mycophenolate azathioprine or an oral calcineurin inhibitor is allowed).
  • Participants with Urine Protein-to-Creatinine Ratio (UPCR) greater than (>) 339 milligrams per millimole (mg/mmol), and/or estimated Glomerular Filtration Rate (eGFR) less than 40 milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73 m^2), as calculated by the Modification of Diet in Renal Disease (MDRD) equation.
  • Participants with any active signs, symptoms, or diagnoses considered related to Central Nervous System (CNS) lupus within the past 3 months, or any history of uncontrolled seizures.
  • Other protocol-defined exclusion criteria may apply.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Placebo-jämförare: Placebo

Participants will receive Investigator-recommended SoC.

Participants will receive a single oral dose of a placebo matching Enpatoran tablet twice daily from Day 1 to Day 168.

Experimentell: Enpatoran

Participants will receive a dose of Enpatoran orally twice daily from Day 1 to Day 168.

Andra namn:
  • M5049

Participants will receive Investigator-recommended SoC.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Andel deltagare med Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) 70-svar, definierat som ≥ 70 procent (%) minskning i CLASI-A-poäng från baslinje
Tidsram: Vid vecka 24
Vid vecka 24

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Antal deltagare med behandlingsrelaterade biverkningar (TEAEs), allvarliga biverkningar (SAEs) och biverkningar av särskilt intresse (AESI)
Tidsram: Från dag 1 till vecka 24
Från dag 1 till vecka 24
Antal deltagare med onormala (större än och lika med [>=] grad 3) laboratorieparametrar
Tidsram: Från dag 1 till vecka 24
Från dag 1 till vecka 24
Procentandel deltagare med CLASI-50-svar, definierat som ≥50 % minskning av CLASI-A-poäng från baseline
Tidsram: Vid vecka 4 och 24
Vid vecka 4 och 24
Procentandel av deltagare med BILAG-måttliga till svåra utbrott
Tidsram: upp till vecka 24
upp till vecka 24
Percentage of Participants With British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response
Tidsram: At Week 24

A BICLA response is defined as British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) -improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and less than or equal to [<=] 1 new B.); Here, score A ("Active"): Severely active disease; score B ("Beware"): Moderately active disease; score C ("Contentment"): Mild stable disease; score D ("Discount"): Inactive now but previously active; -no worsening in disease activity (no new BILAG 2004 A scores and <= 1 new B score); -no worsening of total Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score from Baseline; -no significant deterioration (less than [<] 10% worsening) in visual analog Physician's Global Assessment (PGA) and -no treatment failure i.e. protocol-prohibited medications as determined by Endpoint Adjudication Committee (EAC) or premature discontinuation from study treatment).

At Week 24
Percentage of Participants With CLASI-A less than and equal to (<=) 3 at Week 24
Tidsram: At Week 24

CLASI-A assesses the signs of CLE disease activity including erythema, scale, and hypertrophy, active alopecia, and mucous membrane disease, Scores range from 0 to 70 points for CLASI-A score. Mild, moderate, and severe disease corresponds with CLASI activity score ranges of 0 to 9, 10 to 20, and 21 to 70, respectively. Higher scores indicate more disease activity.

At Week 24
Percentage of Participants With BICLA Response and Clinically Meaningful Corticosteroid (CS) Reduction
Tidsram: Day 1 up to Week 12 and thereafter upto Week 24

BICLA Response and clinically meaningful CS reduction, is defined as reduction of daily prednisone-equivalent dose from >= 10 milligrams (mg) at Day 1 to <= 5 mg by the Week 12 visit and sustained through Week 24.

Day 1 up to Week 12 and thereafter upto Week 24
Change from Baseline in Worst Itch Numeric Rating Scale (NRS) Score at Week 24
Tidsram: Baseline and at Week 24

The Worst Itch NRS is a self-rated single item scale designed for assessing worst itch in the past 7 days. The scale utilizes 11-point NRS, scored from of 0 (no itch) to 10 (worst imaginable itch).

Baseline and at Week 24
Change from Baseline in CLASI-A Erythema at Week 24
Tidsram: Baseline and at Week 24

CLASI-A assesses the signs of CLE disease activity including erythema, scale, and hypertrophy, active alopecia, and mucous membrane disease, Scores range from 0 to 70 points for CLASI-A score. Mild, moderate, and severe disease corresponds with CLASI activity score ranges of 0 to 9, 10 to 20, and 21 to 70, respectively. Higher scores indicate more disease activity.

Baseline and at Week 24
Change from Baseline in CLASI-A Scale/Hypertrophy at Week 24
Tidsram: Baseline and at Week 24

CLASI-A assesses the signs of CLE disease activity including erythema, scale, and hypertrophy, active alopecia, and mucous membrane disease, Scores range from 0 to 70 points for CLASI-A score. Mild, moderate, and severe disease corresponds with CLASI activity score ranges of 0 to 9, 10 to 20, and 21 to 70, respectively. Higher scores indicate more disease activity.

Baseline and at Week 24
Change from Baseline in CLASI-A Alopecia at Week 24
Tidsram: Baseline and at Week 24

CLASI-A assesses the signs of CLE disease activity including erythema, scale, and hypertrophy, active alopecia, and mucous membrane disease, Scores range from 0 to 70 points for CLASI-A score. Mild, moderate, and severe disease corresponds with CLASI activity score ranges of 0 to 9, 10 to 20, and 21 to 70, respectively. Higher scores indicate more disease activity.

Baseline and at Week 24
Percentage of Participants With a Cutaneous Lupus Activity Investigator's Global Assessment-Revised (CLA-IGA-R OMC) Score of 0 or 1 and at Least a 1-Point Reduction at Week 24
Tidsram: At Week 24

The CLA-IGA-R is assessed by the investigator, who assigns rater to assign scores to 3 individual domains (e.g. erythema, other morphologic characteristics - OMC [scales, edema)/infiltration and secondary change (vesicles, erosion, crusting)] and follicular activity). Clinicians assess the severity of the first 2 domains of erythema and OMC from 0 (Clear) to 4 (Severe); they assess the severity of the third domain of follicular activity as "absent" or "present." Higher scores indicate more disease activity.

At Week 24
Time to First Moderate/Severe BILAG Flare
Tidsram: Day 1 up to 24 weeks

Median time to first moderate or severe BILAG Flare will be calculated.

Day 1 up to 24 weeks
Percentage of Participants with Corticosteroid (CS) reduction of Daily Prednisone Equivalent Dose
Tidsram: Day 1 up to 24 weeks

CS reduction is defined as reduction of daily prednisone-equivalent dose from >= 10 milligrams per day (mg/day) at Day 1 to <= 5 mg/day by the Week 12 visit and sustained through Week 24.

Day 1 up to 24 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Studierektor: Medical Responsible, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

10 mars 2026

Primärt slutförande (Beräknad)

24 maj 2029

Avslutad studie (Beräknad)

24 maj 2029

Studieregistreringsdatum

Först inskickad

9 januari 2026

Först inskickad som uppfyllde QC-kriterierna

9 januari 2026

Första postat (Faktisk)

12 januari 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

4 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

IPD supporting publicly available results will be evaluated for sharing.

Tidsram för IPD-delning

IPD from completed trials will be publicly available within 6 months after all of the following events:

  • Approval of a product/new indication by major authorities (FDA, EMA, PMDA if requested) with no pending submissions
  • Public results via primary manuscript or trial registry disclosure
  • Legal authority to share data
  • Privacy protections are in place If approval is not sought or development is globally discontinued, data will be publicly available within 18 months after global trial completion. Further information on how to request data can be found on our website bit.ly/IPD21

Kriterier för IPD Sharing Access

Qualified researchers may propose access to IPD from sponsored trials via https://vivli.org/members/ourmembers/.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ANALYTIC_CODE
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera